Introduction: Symptoms of atrial fibrillation (AF) can significantly affect functioning in daily life and reduce patients’ quality of life (QoL). The severity and type of AF symptoms affects not only patient’s QoL, but can be a cause of the development of emotional and psychological disorders. In addition, frailty syndrome (FS) plays important role from the point of view of developing disability and dependence on others, as well as reducing QoL. Aim: To assess the symptoms of anxiety and depression, to evaluate the co-occurrence of frailty syndrome and the impact of these factors on the quality of life of patients with AF. Methods: The study used a Polish adaptation of the Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia part III (ASTA part III), the Tilburg Frailty Indicator (TFI) and the Hospital Anxiety Depression Scale (HADS). Results: Analysis showed that anxiety symptoms and depressive symptoms correlate significantly (p < 0.05) and positively with the physical (r = 0.24; p < 0.001, r = 0.29, p = 0.002, respectively), psychological (r = 0.34, p < 0.001, r = 0.49 p < 0.001, respectively) and total quality of life (r = 0.31, p = 0.001, r = 0.414; p < 0.001, respectively) ASTA III domains. A significant (p < 0.05) positive correlation was observed between the TFI total score and the physical (r = 0.34, p < 0.001), psychological (r = 0.36, p < 0.001) and overall quality of life (r = 0.38, p < 0.001) in ASTA III domains. Conclusions: Both FS and depressive and anxiety symptoms significantly affect QoL. Understanding the relationship between anxiety and depressive symptoms, FS and QoL may allow for a more targeted approach to the treatment and care of patients with AF.

Introduction: Due to the SARS-CoV-2 pandemic, there have been fundamental changes to the delivery and operation of healthcare facilities across the world, these changes have significantly impacted how patients with a variety of diseases are treated. We aimed to assess the impact of the COVID-19 pandemic on patient management outcomes among patients with acute coronary syndromes (ACS) and exploring the differences in patients who were treated within and outside the coordinated care programme for patients after ACS (KOS-Zawał).Material and methods: We analysed 472,996 medical records of patients after ACS from 2017 to 2022. The study examined information on deaths in two groups of patients; those included and those not included in the KOS-Zawal.Results: Before COVID-19 pandemic higher mortality rate was shown in the group of patients not covered by the KOS-Zawal benefit compared with patients covered by the benefit (25.5% vs. 15.8%; p<0.0001) decreased significantly. During the COVID-19 a significant higher incidence of death was shown in the group of patients not covered by the KOS-Zawal compared with patients covered by the program (18% vs. 7.9%; p<0.0001). Compared to the time before and during COVID-19, the number of deaths among patients not covered (25.5% vs. 18%; p<0.0001) and covered by the KOS-Zawal (15.8% vs. 7.9%, p<0.0001) decreased significantlyConclusions: Patients not covered by KOS-Zawal had a significantly higher mortality rate compared to those receiving the program during the pandemic. The pandemic significantly affected patients under KOS-Zawal care, with a reduced mortality.